Kyle Rose

Stock Analyst at Canaccord Genuity

(2.64)
# 2,015
Out of 5,124 analysts
115
Total ratings
52.69%
Success rate
13.43%
Average return

Stocks Rated by Kyle Rose

Insulet
Dec 17, 2025
Maintains: Buy
Price Target: $432$450
Current: $284.24
Upside: +58.32%
Smith & Nephew
Feb 26, 2025
Maintains: Hold
Price Target: $27
Current: $32.81
Upside: -17.71%
Stryker
Jan 29, 2025
Maintains: Buy
Price Target: $420$435
Current: $351.47
Upside: +23.77%
Globus Medical
Dec 20, 2023
Maintains: Buy
Price Target: $67$71
Current: $87.31
Upside: -18.68%
Enovis
Dec 20, 2023
Maintains: Buy
Price Target: $65$71
Current: $26.64
Upside: +166.52%
InMode
Oct 13, 2023
Downgrades: Hold
Price Target: $55$22
Current: $14.69
Upside: +49.76%
The Beauty Health Company
Aug 25, 2023
Assumes: Buy
Price Target: $10
Current: $1.39
Upside: +619.42%
Alphatec Holdings
Aug 4, 2023
Maintains: Buy
Price Target: $17$22
Current: $21.04
Upside: +4.56%
DexCom
Jul 28, 2023
Maintains: Buy
Price Target: $135$150
Current: $66.37
Upside: +126.01%
Vicarious Surgical
May 31, 2023
Maintains: Buy
Price Target: $360$270
Current: $2.17
Upside: +12,342.40%
Maintains: Buy
Price Target: $24$27
Current: $19.72
Upside: +36.92%
Reiterates: Buy
Price Target: $15
Current: $1.18
Upside: +1,171.19%
Reiterates: Buy
Price Target: $15
Current: $32.73
Upside: -54.17%
Maintains: Market Perform
Price Target: $125$122
Current: $161.96
Upside: -24.67%
Upgrades: Buy
Price Target: $3$4
Current: $5.80
Upside: -31.03%
Downgrades: Hold
Price Target: n/a
Current: $7.44
Upside: -
Downgrades: Hold
Price Target: $165$125
Current: $89.92
Upside: +39.01%